leadf
logo-loader
viewEmpower Clinics Inc.

Empower Clinics Inc ramps up coronavirus testing at Portland clinic; collects signitures for psilocybin ballot initiative

The life sciences group has established a four-phase antibody testing program using its RAPID COVID-19 test kits.

Empower clinic
In May, Empower launched Dosed Wellness, a psychedelics division leveraging the company’s network of physicians and clinics

Empower Clinics Inc (CSE:CBDT) (OTCQB:EPWCF) announced Wednesday that it has initiated phases one and two of coronavirus (COVID-19) testing at its clinic in Portland, Oregon. 

As reported in April, the life sciences group has established a four-phase antibody testing program using its RAPID COVID-19 test kits.

“Our team has performed COVID-19 tests for groups and individuals both remotely and inside our clinics as part of our testing program,” CEO Steven McAuley said in a statement. “With national rates of COVID-19 currently spiking, it is critical that we expand our testing services to our large patient base in Oregon.”

READ: Empower Clinics reaches third stage of its four-phase national roll-out of coronavirus testing

Additionally, Empower said it is collecting signatures at the Portland clinic in support of a proposed state ballot initiative that would create a licensed and supervised-psilocybin-assisted therapy system. 

The measure, IP34, requires 145,000 signatures to appear on the ballot in November. So far it has gathered 142,480, according to yesonIP34.org. 

In May, Empower launched Dosed Wellness, a psychedelics division leveraging the company’s network of physicians and clinics, research opportunities and a base of more than 165,000 patients.

“A major aspect of our new psychedelics division, Dosed Wellness, is assisting in the development of new legal markets from the ground up,” Dustin Klein, Empower senior vice president of Business Development said.

“We are so pleased that our Portland clinic is a safe location to collect signatures for Oregon’s IP34 ballot initiative.”

The Vancouver-based company pointed to studies at institutions such as Johns Hopkins, UCLA, and NYU that have shown that psilocybin is uniquely effective in treating depression, anxiety, trauma like PTSD and addiction.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Empower Clinics Inc.

Price: 0.07 CAD

CSE:CBDT
Market: CSE
Market Cap: $13.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Empower Clinics Inc. named herein, including the promotion by the Company of Empower Clinics Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Empower Clinics subsidiary Kai Labs signs major contract with tv and movie...

Empower Clinics (CSE: CBDT- OTC: EPWCF) CEO Steven McAuley joined Steve Darling from Proactive with news the company’s subsidiary Kai Laboratories has signed a major contract for PCR testing in the film and tv industry. McAuley telling Proactive this deal represents a repeat and significantly...

1 week, 5 days ago

2 min read